Full Press Release Details
Files Orphan Drug Application for Use of Iomab-B in Treating
Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients
Drug Designation Could Provide Faster Regulatory Review and Financial Incentives
YORK, NY - November 23, 2015 Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"),
is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.
Actinium announced today that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration
(FDA) for Iomab-B, a radioimmunotherapeutic that conditions refractory and relapsed Acute Myeloid Leukemia (AML) patients for
a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). The Company has recently
submitted an Investigational New Drug (IND) application for Iomab-B with the FDA and is preparing for a pivotal, Phase 3 trial.
J. Dave, Ph.D., MBA, CEO of Actinium stated, "We are pleased to have filed an Application for Orphan Drug Designation for
Iomab-B. We are confident that Iomab-B meets the criteria for Orphan Drug Designation and are eager to begin the Phase 3, pivotal
trial for Iomab-B. Acute Myeloid Leukemia is the most common acute leukemia affecting adults and accounts for the largest number
of annual deaths due to leukemia. Refractory and relapsed AML patients, particularly elderly patients, have very few, if any,
treatment options other than a Bone Marrow Transplant. Unfortunately, many of these patients cannot tolerate the intensive chemotherapy
given prior to BMT. We believe that Iomab-B will allow a greater number of AML patients to receive a BMT and could be a paradigm
shift in the way AML patients are treated."
Actimab-A, which is intended to treat newly diagnosed AML patients over the age of 60, received Orphan Drug Designation on December
1, 2014. Results from the Phase 1 portion of Actimab-A's Phase1/2 trial will be presented at the 57th American
Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida on December 4 - 8, 2015. Actimab-A data, including
patients from the fourth and final cohort, will be presented in a poster session on December 7, 2015 at 6 pm EST.
FDA, through its Office of Orphan Products Development (OOPD), grants orphan status to drugs and biologic products that are intended
for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people
in the U.S. Orphan drug designation provides a drug developer with certain benefits and incentives, including a period of marketing
exclusivity if regulatory approval is ultimately received for the designated indication; potential tax credits on U.S. clinical
trials; eligibility for orphan drug grants; and waiver of certain administrative fees.
is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed
by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells.
This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation
in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic
leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM).
When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while
avoiding effects of radiation on most healthy tissues.
Actinium Pharmaceuticals
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be
used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.
The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients
over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is
continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter
Statements for Actinium Pharmaceuticals, Inc.
news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results
to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product
development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.
Director, Finance and Corporate Development
Pharmaceuticals, Inc.